Free Industry a no-show as Sens. Grassley and Wyden hold hearing on drug pricing February 01, 2019Vol.45 No.05By Claire Dietz
Free Gottlieb: FDA to expand real-world data infrastructure to enhance AI capabilities February 01, 2019Vol.45 No.05By Matthew Bin Han Ong
FreeGuest Editorial The Prostate Cancer Prevention Trial and nine lessons in prostate cancer medicine February 01, 2019Vol.45 No.05By Otis W. Brawley
FreeGuest Editorial 20-year follow-up data are in: Prostate cancer prevention works; concerns about high-grade disease dismissed February 01, 2019Vol.45 No.05By Ian Thompson Jr., Phyllis Goodman and Catherine Tangen
Conversation with The Cancer LetterFree Brawley aims to create a “huge collaboration” in research on disparities January 25, 2019Vol.45 No.04By Paul Goldberg
Free FDA approves 19 new cancer drugs and biologics in 2018—and don’t forget two new endpoints and “real-time” review January 25, 2019Vol.45 No.04By Claire Dietz and Matthew Bin Han Ong
Conversation with The Cancer LetterFree Why austerity measures amid Congressional generosity? Sharpless explains the counterintuitiveSharpless explains the counterintuitive January 25, 2019Vol.45 No.04By Paul Goldberg
Trials & Tribulations Giving every patient an opportunity to participate in and benefit from cancer progress January 18, 2019Vol.45 No.03By Monica M. Bertagnolli
New MSK rules prohibit service on boards of for-profit entities in healthcare January 18, 2019Vol.45 No.03By Paul Goldberg
